Discovery of a new treatment for kidney cancer

News: Discovery of a new treatment for kidney cancer, we always want to provide you with special news content to satisfy you via our news site News News website, a site News created in 2016 to offer you a complete news content on the Arab and international scene Many reliable sources of information, where we are eager to follow all that is new on the political scene , technical and sports and other areas of interest for our readers to post on the news site, the discovery of a new treatment for kidney cancer The researchers suggest that ZHX2 is a new drop Possible treatment for renal cell carcinoma, the most common type of kidney cancer. [1]

Discovery of a new treatment for kidney cancer
Scientists at the Comprehensive Cancer Center of the University of North Carolina have discovered a possible therapeutic drop for kidney cancers that have a change common genetics. That helps to nourish the nutrients of tumors, and their latest discoveries show a possible new way for cancer treatment.

Kidney Cancer
More than 90 percent of the most common type of kidney cancer has a genetic change leading to the loss of an important gene to prevent tumors called VHL. They discovered that a protein called ZHX2 accumulates on top of these cells and helps trigger other cancer-related signals, which leads to their growth. The results suggest that ZHX2 is a new therapeutic cycle of renal cell carcinoma, the most common type of kidney cancer.

Jane VHL
"If VHL is lost, it will accumulate a lot of ZHX2 protein, which will transmit signals into the brain," said Cheng Chang of the University of North Carolina, assistant professor at the # 39, University of North Carolina. Supports the occurrence of kidney cancer, and this protein may be a potential therapeutic target, used to treat kidney cancer alone or in combination with other drugs, and the next step is to try to know how we can target it therapeutically.

Neuronal Cell Cancer
Carcinoma of neuronal cells is the most common type of kidney cancer, accounting for about 70% of all cases.According to researchers, about 90% of patients with renal cell carcinoma, having Genetic mutations or changes that make them lose VHL function When VHL function disappears, cells can accumulate signals that lead to vascular growth. Zhang said, "VHL is the most important tumor suppressor in cancer cells of the kidney cell.There are detailed reports showing that from the beginning of the development of the tumor to the malignant tumor – during the development of kidney cancer whole – VHL plays a central role We understand how VHL loss contributes to kidney cancer and how it can be targeted as a treatment for these side effects that occur in kidney cancer. "

Drugs Approved [19659003] FDA-approved drugs inhibit cellular signaling involved in the production of abnormal blood vessels, a combined effect of the loss of VHL, which is a standard care for pure renal cell carcinoma. Drug development or resistance, so Zhang and his colleagues wanted to look for other targets that accumulate in cells without VHL function, which contribute to the abnormal growth of cancer.

The technique developed by the researchers
developed a screening technique to detect new molecules that may contribute to cancer when VHL is lost, which led them to determine that cancer cells of the kidneys generally lacked more than ZHX2. On the ZHX2 lab models, they prevent the growth of cancer cells and the invasion and spread of cancer, they have also been implicated in signs that help cancer cells to grow, said Dr. William Kim from the University of North Carolina. With the development of targeted molecular therapies Agat is based on the immune system, however, additional treatments are needed to reach more patients with metastases. "The vast majority of kidney cancers have mutations in VHL, and in the last decade or more, we have achieved a large number of major treatments for kidney cancer," said Kim, associate professor of medicine and genetics at the University of North Carolina.More than 12 types of treatments approved by the FDA, but many are similar.These studies are important.They identify the underlying biology of kidney cancer and identify new and distinct ways to develop antiviral drugs. "

This study was supported by the US Department of Defense Career Development Award, the University Cancer Research Fund and the National Cancer Institute. Individual researchers were supported by the V Cancer Research Foundation, the Kimmel Scholar Award, Susan G. Komen, The Mary Kay Foundation, the US Department of Defense, the Howard Hughes Medical Institute, the NCI, and the National Council. for medical research and biomedicine.

Source: Science Daily